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Introduction
•R
 oux-en-y gastric bypass (GB) surgery has been increasingly employed to treat the
morbidities of obesity
• In 2005, Service et al (1) reported hyperinsulinemic hypoglycemia in 6 GB patients
who were found to have anatomic changes in islet cells
• Since that time, postprandial hypoglycemia has become increasingly recognized as
a late complication of GB
• Carbohydrate (CHO) restriction is recommended as initial therapy but is not always
effective in reducing hypoglycemia
• Alphaglucosidase inhibitor (AGI) therapy has been suggested as a second line
therapy
• We report the first collection of GB hypoglycemic patients who were successfully
treated with long-term AGI therapy

Summary of Cases 1, 2, 3 and 4
Table 1
Case 1

Case 2

Case 3

Case 4

42

32

56

50

14.4

16.4

Lab error

46.7

4.2

2.8

Lab error

10.6

Negative

Not done

Not done

Negative

Carb restricted diet
& acarbose

Carb restricted diet &
acarbose

Carb restricted diet &
acarbose

**Carb restricted diet, allergic
to acarbose and miglitol

4 years

3 years

2 years

6 months

PP* BG nadir (65-99
mg/dl)
Insulin (<29.2
ulU/mL)
C-peptide ng/ml
CT Abdomen
Treatment
Time of follow-up

*PP = postprandial following mixed meal (all patients symptomatic)
**Decrease in PP hypoglycemia with AGI therapy but rash required discontinuation

Case 1
•4
 2 F who underwent GB 3 years prior presented for evaluation of hypoglycemia
• Patient met criteria for Whipple’s Triad:
– Experienced sweating, palpitations, tremor and neuroglycopenic symptoms 2-4 hours
postprandial
– Documented capillary glucose (BG) of 35-50 mg/dl
– Symptoms resolved with simple CHO
• Baseline testing ruled out adrenal, thyroid, renal and hepatic dysfunction
• Mixed 75g meal endocrine testing revealed:
– Fasting BG 83 mg/dL
– 115 minute symptomatic BG of 42 mg/dL with simultaneous serum insulin 14 ulU/mL (<29.2
ulU/mL)
– C-peptide 4.2 ng/ml (0.9-6 ng/mL)
– Beta hydroxybutyric acid of 0.08 mmol/L (0.0-0.42 mmol/L)
– Sulfonylurea screen negative
– CT negative for pancreatic mass
• Because her hypoglycemia was exclusively postprandial, empiric therapy was
instituted rather than pursuing invasive testing to rule out insulinoma
• She started a 30-gram per meal CHO restricted diet and initially responded
• However increasing CHO intake resulted in symptomatic hypoglycemia
• Pre-meal AGI therapy of 50mg TID was initiated with meals
• At 3-year follow-up patient denies symptomatic postprandial hypoglycemia except
when she omits AGI therapy

Discussion (cont.)

•G
 lucagon like peptide-1 levels were found to be significantly increased in GB patients
with symptomatic hypoglycemia compared to asymptomatic GB patients (4)
• CHO restriction is the first step instituted to treat symptomatic GB hypoglycemia
• Kellogg et al (5) described 10 out of 12 GB patients had complete or partial improvement
of symptomatic hypoglycemia with low CHO diet
• Acarbose has been shown to decrease postprandial hyperglycemia after mixed meal
testing as well as attenuate the rise in insulin and GLP-1 levels (6)
• Kellogg et al (5) placed 2 patients on AGI therapy after failing low CHO diet therapy
with 1 experiencing improvement
• Moreira et al (7) added AGI to verapamil therapy to a single patient with resolution of
hypoglycemia
• Hanaire et al (8) reported the use of AGI therapy in a single patient decreased
hypoglycemia after an 8 month follow-up

Discussion

•M
 ost recent review of symptomatic hypoglycemia in GB patients has described an
incidence between 0.2-6% (2)
• To date 89 cases have been reported (Table 2)

Conclusions

•W
 e are the first to demonstrate the long-term effectiveness of AGI therapy in GB
patients with postprandial hypoglycemia who fail dietary carbohydrate restriction

Table 2
Cases

Mean age
(years)

Time of Onset after
GB* (months)

Lowest Glucose
Value (mg/dl)

89

44

28.6

41.4
(at time of symptoms)

4

43

42

37
(mixed meal nadir)

Ritz et al
Current Series

*GB = roux-en-y gastric bypass

•A
 lthough we did not definitively rule out insulinoma, given the response to AGI therapy
we elected not to perform other invasive testing on all patients
• Our mixed meal testing confirmed inappropriate hyperinsulinemia in the presence of
symptomatic hypoglycemia
• The etiology of GB hypoglycemia remains unclear
• Symptoms from dumping syndrome can mimic post-prandial hypoglycemia
• However, dumping syndrome occurs weeks to months after surgery versus 1-2 year
delay in GB hypoglycemia patients
• Some patients were found to have changes in islet cells consistent with noninsulinoma
pancreatogenous hypoglycemia (NIPHS) (1)
• However, Meirer et al (3) did not find islet cell hypertrophy or hyperplasia
• Attention has focused on exaggerated secretion of incretins after meal ingestion
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